Sandu Pharmaceuticals (524703) Q2 24/25 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2024 were reviewed and approved by the Board on 14th November 2024.

• Amendment in the Code of Conduct for Prevention of Insider Trading was approved in compliance with SEBI regulations.

Financial highlights

• Standalone revenue from operations for Q2 FY25 was ₹1,770.49 lakhs, up from ₹1,660.71 lakhs in Q2 FY24; half-year revenue was ₹3,475.03 lakhs, up from ₹3,426.42 lakhs year-over-year.

• Standalone net profit for Q2 FY25 was ₹50.02 lakhs, compared to ₹55.16 lakhs in Q2 FY24; half-year net profit was ₹66.71 lakhs, compared to ₹66.13 lakhs year-over-year.

• Consolidated revenue for Q2 FY25 was ₹1,770.49 lakhs, with half-year revenue at ₹3,475.03 lakhs.

• Consolidated net profit for Q2 FY25 was ₹49.52 lakhs, with half-year net profit at ₹65.98 lakhs.

• Earnings per share (EPS) for the half year was ₹0.69 (basic and diluted) on a face value of ₹10 per share.

Outlook and guidance

• No explicit forward-looking guidance provided, but the company continues to focus on compliance and operational efficiency.